Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“HOT off the press
Just in time for American Society of Clinical Oncology (ASCO) annual meeting.
Delighted to share our fresh new paper in Journal of Clinical Oncology’s Comments & Controversies section.
”Should We Call Every Cancer a Rare Cancer?”
We propose a tiered classification framework that could reshape how we define, refine and treat rare cancers.
Amid all the incredible ASCO26 sessions, this one is worth a read in American Society of Clinical Oncology (ASCO) ‘s flagship journal.
Thrilled to co-author this with the brilliant Chadi Nabhan renowned book author, podcaster, and one of the sharpest minds in oncology.”
Title: Should We Call Every Cancer a Rare Cancer?
Authors: Vivek Subbiah, Chadi Nabhan
Read the article here.
Other articles about Rare Cancers on OncoDaily.